Lexicon Pharmaceuticals Inc (LXRX) Common Stock USD0.001 144A
0.31%- This stock can be held in a
Stocks and Shares ISA
$0.03
(4.37%)$0.03
(4.37%)Company Information
About this company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
Key people
Key facts
- EPICLXRX
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS5288723027
- Market cap$278.45m
- Employees103
- Shares in issue365.56m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.